Liping Zuo

Liping Zuo

Auto-generated profile, based on publicly available information

Liping Zuo

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan 430022

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Molecular Therapy
Verified
Journal Article
Open access
AXAoshuang Xu
Aoshuang Xu
JZJiasi Zhang
Jiasi Zhang
LZLiping Zuo
Liping Zuo
HYHan Yan
Han Yan
LCLei Chen
Lei Chen
YHYu Hu
Yu Hu
N6-methyladenosine (m6A), as the most pervasive internal modification of eukaryotic mRNA, plays a crucial role in various cancers, but its role in multiple myeloma (MM) pathogenesis has not yet been investigated. In this study, we revealed significantly decreased m6A methylation in plasma cells (PCs) from MM patients and showed that the abnormal m6A level resulted mainly from upregulation of the demethylase fat mass and obesity-associated protein (FTO). Gain- and loss-of-function studies demonstrated that FTO plays a tumor-promoting and pro-metastatic role in MM. Combined m6A and RNA sequencing (RNA-seq) and subsequent validation and functional studies identified heat shock factor 1 (HSF1) as a functional target of FTO-mediated m6A modification. FTO significantly promotes MM cell proliferation, migration, and invasion by targeting HSF1/HSPs in a YTHDF2-dependent manner. FTO inhibition, especially when combined with bortezomib (BTZ) treatment, synergistically inhibited myeloma bone tumor formation and extramedullary spread in NOD-Prkdcem26Cd52il2rgem26Cd22/Nju (NCG) mice. We demonstrated the functional importance of m6A demethylase FTO in MM progression, especially in promoting extramedullary myeloma (EMM) formation, and proposed the FTO-HSF1/HSP axis as a potential novel therapeutic target in MM.

1 February 2025 in Carcinogenesis
Verified
Journal Article
Closed access
DLDehu Li
Dehu Li
BQBing Qiao
Bing Qiao
QCQianwen Cheng
Qianwen Cheng
LCLei Chen
Lei Chen
FZFei Zhao
Fei Zhao
CSChunyan Sun
Chunyan Sun
Macrophage migration inhibitory factor (MIF) emerged in recent years as an important cytokine with a pleiotropic spectrum of biological functions implicated in the pathogenesis of inflammatory diseases and malignancies. A growing body of research indicates that the overexpression of MIF is prevalent across a variety of solid tumors. Howbeit, there are fewer studies regarding the expression and clinical significance of serum MIF in multiple myeloma (MM) patients. In this study, we investigated the clinical significance of serum MIF in newly diagnosed MM (NDMM) patients and explored the effect of exogenous MIF on the proliferation, migration, and invasion of MM cells in vitro. Herein, our study revealed that NDMM patients exhibited markedly elevated serum MIF levels compared to healthy adults. High levels of MIF were associated with advanced International Staging System (ISS) stage and the Second Revision of the International Staging System (R2-ISS) stage. Besides, NDMM patients with high levels of MIF were prone to have a higher incidence of hypercalcemia, renal insufficiency, high tumor burden, and extramedullary lesions. Moreover, we found that serum MIF, creatinine, and lactate dehydrogenase levels were independent risk factors for predicting poor progression-free survival and overall survival in NDMM patients. Meanwhile, in vitro experiments revealed that MIF can promote the proliferation of MM cells and enhance their migration and invasion. Our study confirmed that NDMM patients with high serum MIF levels showed poor clinical characteristics and inferior prognosis. Therefore, MIF may serve as a promising biomarker in the clinical practice of MM.

27 March 2025 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
XWXuezhu Wang
Xuezhu Wang
LZLiping Zuo
Liping Zuo
YYYanying Yu
Yanying Yu
XXXinyi Xiong
Xinyi Xiong
JXJian Xu
Jian Xu
JLJian Li
Jian Li
Plasma cell disorders (PCDs) are marked by the clonal proliferation of abnormal plasma cells and bone marrow plasma cells (BMPCs), causing various clinical complications. These PCDs include subtypes with distinct clinical features. Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are more common and relatively well-studied. In contrast, primary light-chain amyloidosis (AL) and POEMS syndrome (POEMS) are rare and remain less understood. To investigate the role of clonal hematopoietic (CH) mutations and potential interconnections in these diseases, we sequenced CH mutations in lymphoid and myeloid lineages, as well as myeloma driver gene mutations, in BMPCs from affected patients. Recurrent lymphoid CH mutations (in FAT1, KMT2D, MGA, and SYNE1) and myeloma driver gene mutations (in ZFHX3 and DIS3) were found in the dominant clonal and subclonal plasma cell populations. These moderately aging-associated lymphoid CH mutations had a higher burden in MM than in AL or POEMS. Binary matrix factorization of these mutations revealed the subgroups associated with progression-free survival (PFS) (observed in MM, AL, and POEMS), age at diagnosis (in AL and POEMS), serum differential free light chain (dFLC) levels, plasma cell burden (in AL), and serum vascular endothelial growth factor (VEGF) levels (in POEMS). Moreover, the poor PFS associated with MGA or SYNE1 mutations was confirmed across MM, AL, and POEMS. CH mutations partially explained the shared pathogenesis of MM, AL, POEMS, and MGUS, and helped identify patient subgroups with specific clinical features.